Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.

Humans Female Trastuzumab / therapeutic use Ovarian Neoplasms / drug therapy Receptor, ErbB-2 / genetics Neoplasm Recurrence, Local / drug therapy Adenocarcinoma, Clear Cell / drug therapy Antineoplastic Agents, Immunological / therapeutic use Camptothecin / analogs & derivatives Middle Aged Immunoconjugates / therapeutic use

Journal

JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370

Informations de publication

Date de publication:
Jun 2024
Historique:
medline: 21 6 2024
pubmed: 21 6 2024
entrez: 21 6 2024
Statut: ppublish

Résumé

Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.

Identifiants

DOI: 10.1200/PO.23.00686 PMID: 38905574
pubmed: 38905574
doi: 10.1200/PO.23.00686
doi:

Substances chimiques

Trastuzumab P188ANX8CK
Receptor, ErbB-2 EC 2.7.10.1
ERBB2 protein, human EC 2.7.10.1
trastuzumab deruxtecan 5384HK7574
Antineoplastic Agents, Immunological 0
Camptothecin XT3Z54Z28A
Immunoconjugates 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2300686

Auteurs

Ben L Kong (BL)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
ORCID: 0000-0002-9019-6961

Jayne M Stommel (JM)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
ORCID: 0000-0003-2485-7992

Jamie M Keck (JM)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.

David Kilburn (D)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.

Aaron Streblow (A)

Oregon Health & Science University School of Medicine, Portland, OR.
ORCID: 0000-0002-8661-5975

Julian Egger (J)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
ORCID: 0000-0001-8418-0069

Allison L Creason (AL)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
ORCID: 0000-0001-5724-1276

Christopher G Suciu (CG)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR.

Alexander R Guimaraes (AR)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Department of Pathology, Oregon Health & Science University, Portland, OR.
ORCID: 0000-0003-4601-9340

Christopher L Corless (CL)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR.

Gordon B Mills (GB)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.

Tanja B Pejovic (TB)

Knight Cancer Institute, Oregon Health & Science University, Portland, OR.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Trastuzumab › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Adénocarcinome à cellules claires › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › Composés hétérocycliques › Alcaloïdes › Camptothécine › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Exceptional Response to Trastuzumab Deruxtecan...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunoconjugués › Exceptional Response to Trastuzumab Deruxtecan...